Cancer immune resistance: can theories converge?

Immune oncology (IO) is challenged to expand its usefulness to a broader range of cancers. A second generation of IO agents acting beyond the realm of Checkpoint Inhibitor Therapy (CIT) is sought with the intent of turning immune-resistant cancers into appealing IO targets. The published literature...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Rongze, Turan, Tolga, Samayoa, Josue, Marincola, Francesco M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Portland Press Ltd. 2017
Materias:
Review Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7289003/
https://www.ncbi.nlm.nih.gov/pubmed/33525800
http://dx.doi.org/10.1042/ETLS20170060

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7289003/
https://www.ncbi.nlm.nih.gov/pubmed/33525800
http://dx.doi.org/10.1042/ETLS20170060

Ejemplares similares